

Edgar Filing: XOMA LTD /DE/ - Form 8-K/A

XOMA LTD /DE/  
Form 8-K/A  
January 09, 2004

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

AMENDMENT NO. 1

on

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): December 18, 2003

XOMA LTD.

-----  
(Exact name of registrant as specified in its charter)

BERMUDA

-----  
(State or other jurisdiction of incorporation)

0-14710  
(Commission File Number)

52-2154066  
(IRS Employer Identification No.)

2910 Seventh Street, Berkeley, California

94710

-----  
(Address of principal executive offices)

(Zip code)

Registrant's telephone number, including area code

(510) 204-7200  
-----

-----  
(Former name or former address, if changed since last report)

Item 5. Other Events

## Edgar Filing: XOMA LTD /DE/ - Form 8-K/A

As announced on December 18, 2003, Alexion Pharmaceuticals, Inc. and XOMA Ltd. agreed to collaborate for the development and commercialization of an antibody to treat chemotherapy-induced thrombocytopenia.

A copy of the press release is attached hereto as Exhibit 1 and is incorporated herein by reference. A copy of the agreement governing the collaboration is attached hereto as Exhibit 2 and incorporated herein by reference.

### Item 7. Exhibits

1. Press Release dated December 18, 2003. \*
2. Co-Development and Co-Commercialization Agreement, dated as of December 17, 2003, by and between Alexion Pharmaceuticals, Inc. and XOMA (US) LLC (with certain confidential information omitted, which omitted information is the subject of a confidential treatment request and has been filed separately with the Securities and Exchange Commission).

---

\* Previously filed.

### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 9, 2004

XOMA LTD.

By: /s/ Christopher J. Margolin

-----  
Christopher J. Margolin  
Vice President, General  
Counsel and Secretary

### EXHIBIT INDEX

Number	Description
-----	-----

## Edgar Filing: XOMA LTD /DE/ - Form 8-K/A

1. Press Release dated December 18, 2003. \*
2. Co-Development and Co-Commercialization Agreement, dated as of December 17, 2003, by and between Alexion Pharmaceuticals, Inc. and XOMA (US) LLC (with certain confidential information omitted, which omitted information is the subject of a confidential treatment request and has been filed separately with the Securities and Exchange Commission).

---

\* Previously filed.